Lamivudine/Zidovudine Teva

RSS

lamivudine / zidovudine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Lamivudine/Zidovudine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine/Zidovudine Teva.

This EPAR was last updated on 20/04/2018

Authorisation details

Product details
Name
Lamivudine/Zidovudine Teva
Agency product number
EMEA/H/C/001236
Active substance
  • lamivudine
  • zidovudine
International non-proprietary name (INN) or common name
lamivudine / zidovudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR01
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva Pharma B.V. 
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
28/02/2011
Contact address
Teva Pharma B.V.
Swensweg 5
2031GA Haarlem
The Netherlands

Product information

18/12/2018 Lamivudine/Zidovudine Teva - EMEA/H/C/001236 - IB/0018

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Lamivudine/Zidovudine Teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings